07 -08
May

Venture Capital & Private Equity

Le Meridien Cambridge

What to expect

Timely information, interactive format

Real insights are shared in conversations, not lectures. That’s why our unique roundtable format guarantees real learning and ensures you only attend discussions that deliver value to you.

Join as many as four roundtable discussions, each with up to 20 other subject experts, networking with top-level peers in an informal, relaxed and sociable environment.

Meet Our Facilitators

Our panel of facilitators plays a key role in shaping the agenda for the day. Whilst we’re busy connecting with the best industry experts, take a look at our facilitators.

Caitlyn Harvey

Vice President, Head of CMC Convergent Therapeutics, Inc.

Claire Elizabeth Smith

Partner SpringTide Ventures

Doug Zingale

Managing Partner Blue Goose Capital

David Sherris

CEO Attivare Therapeutics

Session – Next Generation OV and New Combinational Approaches for Treatment of Solid Tumors 
Dr. Sherris has over 30 years’ experience in translational medicine involving basic research, pharmaceutics and diagnostics.  Dr. Sherris has been a successful serial entrepreneur developing biotechnology companies from the ground up, devising corporate strategy, enacting programs and carrying companies through funding and acquisition.  Dr. Sherris prides himself as a “roll up your sleeves” CEO, entrepreneur, business development officer, drug developer and scientist, not simply a delegator. Dr. Sherris has worked with venture capital companies where he has both advised and raised finances for biotech companies.  Dr. Sherris has been employed by pharmaceutical and biotechnology companies to manage external (academic groups and contract research organizations) and internal (directly manage, augment and expand internal scientific programs) research and development. Dr. Sherris has been a frequently invited guest speaker at biopharmaceutical business and scientific conferences, a published author and holder of patents in a wide range of therapeutic areas including oncology, ophthalmology, dermatology, neurology, gene therapy and infectious disease.  Dr. Sherris has held positions of increasing responsibility in public and private companies. Dr. Sherris has developed drugs from the bench to the clinic, partnered technologies to pharmaceutical companies and raised capital for companies at the triple digit million dollar levels.

Gopi Vudathala

Global Head, Regulatory Affairs CMC Incyte Corporation

Dr. Vudathala, Ph.D., is currently Global Head, RA CMC at Incyte Corporation. He was Formerly Executive Director of RA CMC at Intarcia Therapeutics, Head of Quality Advocacy at GSK Vaccines and Global Head of Regulatory CMC at Novartis Vaccines. He was also Associate Vice President of Regulatory Affairs CMC at Sanofi-Aventis. He has extensive experience in CMC regulatory strategy for Global Development and Life-Cycle Management Projects and contributed to over 30 NDA and BLA approvals and 60 INDs. Dr. Vudathala has had numerous interactions with global regulators on project related CMC matters as well as on key ICH initiatives. He has published extensively on drug development and regulatory CMC topics. He was on the Regulatory and Quality Advisory Board at the Parenteral Drug Association and a member of the PDA core team on ICHQ12/ Post Approval Changes. He was also previously Vice Chair of the Technical Development and Operations Committee at PhRMA and an active member of the PhRMA CTD Quality Task Force, Genotoxic Impurities Task Force, and a working group member of the FDA Subcommittee for Pharmaceutical Sciences on Process Analytical Technologies and Quality-by-Design. He was also the Chair of the Regulatory Sciences Section of AAPS. Dr. Vudathala is a well-recognized expert on Regulatory CMC and Quality matters and has made several presentations at AAPS, PDA, IIR, Barnett & Proventa International workshops and conferences on CMC, Regulatory, CTD, Drug Device Combination Products and Genotoxic Impurities topics. Dr. Vudathala graduated from the University of Alberta with a Ph.D. in Pharmaceutics and held positions with the Health Protection Branch, Canada, and Procter & Gamble Pharmaceuticals

Gregory Papastoitsis

Chief Process and Manufacturing Officer Ankyra Therapeutics

Dr. Gregory Zarbis-Papastoitsis is the Chief Process and Manufacturing Officer at Ankyra Therapeutics, an immune-oncology company, where he is responsible for all CMC activities. Prior to Ankyra, he was the EVP of Process and Manufacturing at Compass Therapeutics where he oversaw all CMC activities for a CD137 agonist, which is currently in Phase 1/2 clinical studies. Before he was the SVP of development and manufacturing at Eleven Biotherapeutics where he worked on an IL-1 inhibitor that reached pivotal clinical studies for Dry Eye Disease, and an anti-IL6 antibody (successful IND), for Macular Edema. Earlier, he was Associate Director of Process and Analytical Development at Syntonix Pharmaceuticals, where he was responsible for the early development of a long-lasting Factor IX (ALPROLIX®). He also worked on the commercial process of HUMIRA® (Abbott/Abbvie), on the purification process of ONTAK® , an IL2-diphtheria toxin fusion protein (Seragen), on the early development of an antibody-toxin conjugate (aPSMA-DM1) that reached Phase I clinical trials for prostate cancer and an aCCR2 antibody that was in Phase II clinical trials for autoimmune diseases (Millenium Pharma). He received his PhD in Biology at Binghamton University followed by 3 years of post-doctoral studies at Boston University School of Medicine investigating proteases in Alzheimer disease.

Marcus Semones

CSO Erez Capital

Michal Preminger

Former Head of Innovation, East North America Johnson & Johnson Innovation

Tomasz H. Zastawny,PhD, DSc

Strategic Advisor Auxilius Pharma

Robert Gabriel

Board Member, Managing Partner Ashur Capital

Stephan Krause

Executive Director, Cell Therapy Global Quality Bristol Myers Squibb

Robert Gabriel

Board Member, Managing Partner Ashur Capital

Our Agenda

Investment In Clinical Trials & Manufacturing
Future Outlook: Investment Opportunities In Emerging Markets For Clinical Trials & Pharmaceutical Manufacturing

Investment In Drug Discovery & Biotech
OPENING KEYNOTE PRESENTATION

Investment In Clinical Trials & Manufacturing
Enhancing Efficiency and ROI in Clinical Trials Through the Use of Digital Endpoints

Investment In Drug Discovery & Biotech
What Are the Emerging Trends in Venture Capital for Drug Discovery and Biotech Startups?
David Sherris,
CEO,
Attivare Therapeutics

Investment In Clinical Trials & Manufacturing
Can the Boom and Bust Cycle of Biotech Investing be Changed?
Doug Zingale, Managing Partner, Blue Goose Capital

Investment In Drug Discovery & Biotech
2025 Investment Trends: Transforming Drug Discovery Ventures

Investment In Clinical Trials & Manufacturing
Exploring the Key Strategies for Improving the Cost-Efficiency of Clinical Trials and Increasing ROI for Investors?
Robert Gabriel,
Board Member, Managing Partner,
Ashur Capital

Investment In Drug Discovery & Biotech
Scaling Biotech Ventures: Challenges and Opportunities for Investors in Life Science Startup
Tomasz H. Zastawny,
PhD, DSc, Strategic Advisor,
Auxilius Pharma
CEO,
Armora Biosciences

Investment In Clinical Trials & Manufacturing
Global Expansion of Clinical Trials: Opportunities and Challenges

Investment In Drug Discovery & Biotech
Investment Challenges and Opportunities in Emerging Biotech Markets
Claire Elizabeth Smith,
Partner,
SpringTide Ventures

Investment In Clinical Trials & Manufacturing
PANEL DISCUSSION: Future Outlook: Investment Opportunities in Emerging Markets for Clinical Trials & Pharmaceutical Manufacturing

Investment In Drug Discovery & Biotech
PANEL DISCUSSION: Venture Strategies for Biotech Startups: Building Scalable Innovations in Drug Discovery

Further Information

Interested in attending this virtual roundtable or running your own? Drop us a message today and we will get in touch

Here To Help

Need help registering your team? Just get in touch and a member of the team will be happy to help.

Europe

USA East

USA West

Webinars

Europe

R&D

Investment Dinners & Spotlights

Venture Capital & Private Equity

Venture Capital & Private Equity

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%2012%2016'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Le Meridien Cambridge

Timely information, interactive format

Meet Our Facilitators

Caitlyn Harvey

Claire Elizabeth Smith

Doug Zingale

David Sherris

Gopi Vudathala

Gregory Papastoitsis

Marcus Semones

Michal Preminger

Tomasz H. Zastawny,PhD, DSc

Robert Gabriel

Stephan Krause

Robert Gabriel

Our Agenda

Registration And Welcome

Opening Keynote Presentation

Roundtable Roundtable Tracks

Refreshment Break

Networking / 1-1 Meetings

Roundtable Roundtable Tracks

Roundtable Roundtable Tracks

Refreshment Break

Networking / 1-1 Meetings

Roundtable Roundtable Tracks

Afternoon Refreshment Break

PANEL DISCUSSION

Drinks & Canapes Reception

Further Information

Here To Help

Select days you wish to attend You can add multiple days

VAT Excluded

Select days you wish to attend You can add multiple days

Pass includes:

VAT Excluded

About You

Your Address

About Your Company

This is required field*

Bone/Osteoporosis

Immunology

Orthopaedics

Cardiovascular

Infectious diseases

Pulmonology

CNS

Inflammation

Psychiatry

Dermatology

Internal diseases

Respiratory

Diabetes

Metabolic diseases

Rheumatology

Endocrinology

Nephrology

Surgery

ENT

Neurology

Urology

Gastroenterology

Oncology

Vaccines

Haematology

Ophthalmology

Thrombosis

Rare Diseases

This is required field*

0-10

10-50

Le Meridien Cambridge